Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 11/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.44 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24960096 | 0.98 | NOD1 (0.54) | NOD1FOLH1RIMKLANAALAD2MMP2 | |
| SCHEMBL18082032 | 0.87 | FOLH1 (0.60) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL16704748 | 0.86 | NOD1 (0.57) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL15451428 | 0.86 | NOD1 (0.57) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL17384133 | 0.84 | FOLH1 (0.60) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL12806962 | 0.83 | NOD1 (0.82) | NOD1SLC6A5 | |
| SCHEMBL13640983 | 0.83 | NOD1 (0.82) | NOD1SLC6A5 | |
| SCHEMBL3287762 | 0.83 | FOLH1 (0.64) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL20539219 | 0.83 | FOLH1 (0.64) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL3287759 | 0.83 | FOLH1 (0.64) | NOD1FOLH1RIMKLANAALAD2GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841249-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK A/S (DK) | 2014-09-23 | — | — | US | disclosed |